Clinical Trial Experience
Legit.Health AI scoring is actively deployed in clinical trials with leading pharmaceutical companies. This page summarises our clinical trial engagements across indications, geographies, and use cases.
At a glance
Case study: Decentralised PASI scoring in Phase 3 psoriasis
Study profile
A Phase 3, multicentre, randomised, double-blind, placebo-controlled trial for moderate-to-severe plaque psoriasis, sponsored by a top-10 pharmaceutical company.
| Parameter | Detail |
|---|---|
| Indication | Moderate-to-severe plaque psoriasis |
| Phase | Phase 3 |
| Investigator sites | ~130 |
| Countries | 12 (Argentina, Australia, Belgium, Canada, Denmark, Germany, Hungary, Poland, Portugal, Spain, UK, US) |
| Subjects | ~250 |
| Capture model | Fully decentralised; patients self-capture at home |
| Imaging protocol | 11-perspective full-body (7 full-body + 4 close-ups) |
| Scoring | Automated PASI (APASI) + image quality validation |
| Language localisations | 14 |
| Photography visits | 6 timepoints over the long-term extension phase |
How the technology was used
Patients logged into the Legit.Health mobile application from home and captured 11 standardised photographs covering all four PASI body regions. The app provided step-by-step perspective guidance with visual silhouettes and real-time DIQA quality checks for each image. No clinic visit was required for these assessments.
The AI processed all images automatically, computing:
- Per-region erythema, desquamation, and induration intensity scores
- Pixel-level body surface area (BSA) segmentation per region
- Composite APASI score (0–72)
- DIQA image quality scores per perspective
Scored data was transferred to the sponsor's data science team via automated monthly S3 exports: no central reader, no manual scoring, no delays.
Why this matters
This deployment demonstrated that patients can successfully capture standardised full-body images at home using a standard smartphone, producing scoring data of sufficient quality for a pivotal Phase 3 programme. This model eliminates specific on-site visits, reduces patient burden, and enables continuous severity monitoring between clinic appointments.
Case study: Alopecia safety monitoring in Phase 3 MASH trial
Study profile
A Phase 3 trial for MASH/MASLD (metabolic-associated steatohepatitis) where alopecia was monitored as a safety endpoint.
| Parameter | Detail |
|---|---|
| Indication | MASH/MASLD with alopecia safety monitoring |
| Phase | Phase 3 |
| Capture model | In-clinic |
| Imaging protocol | 4-perspective scalp imaging |
| Scoring | Automated SALT (ASALT) |
How the technology was used
Investigators captured 4 scalp images per patient at scheduled clinic visits. The AI computed ASALT scores to track any alopecia development as a potential adverse event related to the investigational therapy.
Pipeline breadth
Beyond the case studies above, Legit.Health has active engagements spanning multiple indications and use cases:
Indications under active engagement
- Psoriasis: APASI scoring for Phase 3 and retrospective studies
- Acne: ALADIN scoring with automated lesion counting and IGA
- Alopecia: ASALT scoring for scalp assessment
- Atopic dermatitis: ASCORAD and visual sign detection
- Generalized pustular psoriasis (GPP): AI development for GPP identification and GPPGA scoring
Use case diversity
| Use case | Description |
|---|---|
| Severity scoring endpoint | Primary deployment model: automated PASI, IGA, SALT, or SCORAD scoring for efficacy assessment |
| Adverse event detection | AI-based monitoring of treatment-emergent adverse events (e.g., alopecia in MASH trials) |
| Retrospective image analysis | Large-scale analysis of 85,000+ clinical images for 22+ visual signs (erythema, swelling, oozing, excoriations, lichenification, dryness, and more) |
| Patient-facing API integration | API-based scoring integrated into patient self-tracking applications, enabling severity monitoring at scale |
Engagement scale
Active and pipeline engagements involve top-10 and top-20 pharmaceutical companies, spanning:
- Phase 2 and Phase 3 interventional trials
- Long-term extension studies
- Retrospective image analysis programmes
- Patient-facing digital health integrations
Integration models
Legit.Health supports multiple integration architectures to fit the sponsor's infrastructure:
| Model | Description | Example use |
|---|---|---|
| Clinical trials platform | Full web application with investigator portal, patient management, and reporting | Phase 3 decentralised trials |
| Mobile application | Patient-facing app with perspective guidance and DIQA quality control | Home-based capture |
| API integration | RESTful API for programmatic scoring, embeddable in sponsor or CRO platforms | Patient apps, retrospective analysis |
| Data export | Automated S3 transfer, CSV, or structured JSON export to EDC systems | All trial types |
Empieza ahora
Dermatología con IA validada por investigación revisada por pares. De confianza en los principales hospitales de Europa. Rellena el formulario para ver cómo nuestra plataforma con marcado CE puede transformar tu práctica.